BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 17609270)

  • 21. alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli.
    Galili U; Anaraki F
    Glycobiology; 1995 Dec; 5(8):775-82. PubMed ID: 8720075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
    Galili U; Chen ZC; DeGeest K
    Gynecol Oncol; 2003 Jul; 90(1):100-8. PubMed ID: 12821349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
    Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
    World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
    Galili U
    Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza.
    Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G
    Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses.
    Wang Z; Kedzierski L; Nuessing S; Chua BYL; Quiñones-Parra SM; Huber VC; Jackson DC; Thomas PG; Kedzierska K
    J Gen Virol; 2016 Dec; 97(12):3205-3214. PubMed ID: 27902386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of anti-Gal B cells by alpha-Gal ricin1.
    Tanemura M; Ogawa H; Yin DP; Chen ZC; DiSesa VJ; Galili U
    Transplantation; 2002 Jun; 73(12):1859-68. PubMed ID: 12131678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice.
    Scott VL; Patel A; Villarreal DO; Hensley SE; Ragwan E; Yan J; Sardesai NY; Rothwell PJ; Extance JP; Caproni LJ; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1972-82. PubMed ID: 26091432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets.
    Cheng X; Zengel JR; Suguitan AL; Xu Q; Wang W; Lin J; Jin H
    J Infect Dis; 2013 Aug; 208(4):594-602. PubMed ID: 23656978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of cytokine co-expression in individual splenic CD4+ and CD8+ T cells from influenza virus-immune mice.
    Falchetti R; Di Francesco P; Lanzilli G; Gaziano R; Casalinuovo IA; Palamara AT; Ravagnan G; Garaci E
    Immunology; 1998 Nov; 95(3):346-51. PubMed ID: 9824496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review).
    Huai G; Qi P; Yang H; Wang Y
    Int J Mol Med; 2016 Jan; 37(1):11-20. PubMed ID: 26531137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Live-attenuated auxotrophic mutant of Salmonella Typhimurium expressing immunogenic HA1 protein enhances immunity and protective efficacy against H1N1 influenza virus infection.
    Kamble NM; Hyoung KJ; Lee JH
    Future Microbiol; 2017 Jul; 12():739-752. PubMed ID: 28594235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice.
    Hauge S; Madhun AS; Cox RJ; Brokstad KA; Haaheim LR
    Scand J Immunol; 2007 Jan; 65(1):14-21. PubMed ID: 17212762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
    Wen F; Yu H; Yang FR; Huang M; Yang S; Zhou YJ; Li ZJ; Tong GZ
    Arch Virol; 2014 Nov; 159(11):2957-67. PubMed ID: 24957653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection.
    Schmidt T; Dirks J; Enders M; Gärtner BC; Uhlmann-Schiffler H; Sester U; Sester M
    Eur J Immunol; 2012 Jul; 42(7):1755-66. PubMed ID: 22585549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.